8Q4-28045-07701
3 vaccinations
3 coded responses
29 check-ins
3 free-text entries
3 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 928 / CA
- Registered
- 2021-03-26
- Relationship
- Self
- Race
- Multiracial
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-03-26
Registered in v-safe
-
2021-03-26
Dose 1 — Pfizer-BioNTech
-
2021-03-26
Survey response — day 0, dose 1MedDRA: No adverse event — Feeling: Good · Site: Pain · Muscle or body achesFree text: noneMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-27
- 2021-03-29
- 2021-03-31
- 2021-04-01
- 2021-04-09
- 2021-04-16
-
2021-04-18
Dose 2 — Pfizer-BioNTech
- 2021-04-23
- 2021-04-24
- 2021-04-25
- 2021-05-02
- 2021-05-09
- 2021-05-16
- 2021-05-23
- 2021-05-30
- 2021-07-20
- 2021-10-17
-
2022-01-17
Dose 3 — Pfizer-BioNTech
-
2022-01-20
Survey response — days 1–6 daily, dose 3MedDRA: Medical counselling, Oedema peripheral — Feeling: Fair · Site: Pain, Redness, Swelling · Rash, not including the immediate area around the injection site · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professionalFree text: Systemic reaction (other): Swollen armpit · Healthcare visit (other): Nurse hotlineMedDRA releases: 2024-11 · check-in free text available
-
2022-01-20
Report sent to call center — days 1–6 daily, dose 3Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2022-01-21
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain, Swelling · None · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationAdult check-in
-
2022-01-21
Report sent to call center — days 1–6 daily, dose 3Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-01-21
-
2022-01-21
Call successfulNot applicable (accidental reporting or does not believe symptoms are related to vaccine)
- 2022-01-22
- 2022-01-23
- 2022-01-24
- 2022-01-31
- 2022-02-09
- 2022-02-14
- 2022-02-21
- 2022-02-28
-
2022-04-18
Survey response — 3 months, dose 3MedDRA: COVID-19 — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: CovidMedDRA releases: 2024-11 · check-in free text available
-
2022-04-18
Report sent to call center — 3 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-04-22
Call successfulParticipant prefers to complete VAERS report online
- 2023-01-17
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-26 | Pfizer-BioNTech | |
| 2 | 2021-04-18 | Pfizer-BioNTech | |
| 3 | 2022-01-17 | Pfizer-BioNTech | No |
Call center
3 call center cases
3 successful
Free text
Release 6 — day 0, dose 1
Systemic reaction (other): none
Release 10 — days 1–6 daily, dose 3
Release 11 — 3 months, dose 3
Symptoms: Covid
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Medical counselling | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SRO | No adverse event | ✓ | ✓ | ✓ |
| SRO | Oedema peripheral | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release